The impact of COVID-19 on chronic disease management and the implications for pharma marketing

On February 11, 2020, COVID-19 was officially named by the World Health Organisation (WHO). Since then the novel coronavirus causing it, (a severe acute respiratory syndrome) has left its mark on almost every country in the world.

From April to June 2020, Therapy Watch, the syndicated patient record form tracking service from Research Partnership, has been investigating the impact of COVID-19 on chronic disease management amongst its retained panels of physicians. We share selected insights from our Therapy Watch studies across EU5, which are based on research with a variety of specialists in Autoimmune (RA, PsO) & Digestive diseases (IBD), Infectious diseases (HCV, HIV), Osteoporosis, Neurology and Oncology.

In this white paper we offer our perspective on how COVID-19 has influenced patient management and the downstream effect that telemedicine has had on point of care. We look at how patient management is likely to be conducted in the near future, consider the implications for pharmaceutical sales and marketing teams, and the role of market research in supporting strategic decision-making.